BioCardia, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCDA research report →
Price Chart
About the company
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia.
- CEO
- Peter A. Altman
- IPO
- 1996
- Employees
- 17
- HQ
- Sunnyvale, CA, US
Get TickerSpark's AI analysis on BCDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.88M
- P/E
- -1.23
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 14.23
- EV/EBITDA
- -1.36
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -912.37%
- ROIC
- -552.64%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-505,000+88.3%
- Op Income
- $-8,278,000
- Net Income
- $-8,228,000-3.5%
- EPS
- $-1.23+57.6%
- OCF Growth
- +7.4%
- FCF Growth
- +7.3%
- 52W High
- $1.80
- 52W Low
- $0.66
- 50D MA
- $0.97
- 200D MA
- $1.04
- Beta
- 0.49
- RSI (14)
- 37
- Avg Volume
- 206.64K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioCardia said Japan approval work for CardiAMP is advancing and FDA feedback on Helix is expected soon, while cash remains limited but sufficient into 2027.· November 12, 2026
- BioCardia said it has answered PMDA questions for CardiAMP in Japan and is moving toward Shonin submission with its local authorization holder.
- Management expects the initial Japan indication to cover about 20,000 patients, with approval expected 12 months after Shonin submission.
- The company is waiting on FDA feedback on the Helix de novo pathway in the next 6 weeks; if supported, management expects a de novo filing in Q1 2027 and approval in mid-2027.
- The CardiAMP Heart Failure II trial is active at 4 sites, with 7 additional centers being onboarded and no safety issues reported.
- Cash and cash equivalents were $2.2 million at quarter-end, with management saying runway extends into 2027.
BioCardia did not disclose revenue or gross margin on the call. Net cash used in operations was approximately $1.7 million in Q3 2026, flat versus $1.7 million in Q3 2025, and $5.1 million year-to-date versus $4.9 million in the prior-year period. R&D expense was $1.2 million in Q3 2026 versus $0.9 million in Q3 2025, while SG&A was $0.6 million versus $0.55 million. Net loss was $1.8 million in Q3 2026 versus $1.5 million in Q3 2025. Cash and cash equivalents were $2.2 million at quarter-end, which management said provides runway into 2027. Forward-looking, management said CardiAMP Shonin submission in Japan is being prepared, approval is expected about 12 months after submission, and the Helix FDA de novo submission could follow in Q1 2027 with potential approval in mid-2027 if the pathway is supported.
Peter Altman framed the quarter around two regulatory milestones: CardiAMP in Japan and Helix in the U.S. He sounded constructive on Japan, saying PMDA questions have been answered to its satisfaction and that the company is proceeding toward Shonin submission, while also emphasizing the potential commercial scale and the need for partnering beyond the initial post-marketing study. On Helix, he said there is substantial prior clinical data and that BioCardia believes the product should be approvable, but the next step depends on FDA support for the de novo pathway.
David McClung focused on cash usage, expense discipline, and the balance sheet. He said operating cash burn was about $1.7 million in Q3, unchanged from last year, and $5.1 million year-to-date, with cash and cash equivalents of $2.2 million and runway into 2027. He also cited higher Q3 R&D at $1.2 million due to Japan regulatory work and trial support, modestly higher SG&A at $0.6 million, and a net loss of $1.8 million for the quarter.
Analysts asked what a Japan launch could look like, including the post-marketing study and partnering. Management said the launch will essentially be the post-marketing study, likely with around 20 centers and roughly 200 patients, focused mainly on safety and longer-term survival versus historical controls, and that BioCardia expects to remain involved on the ground while partnering for broader expansion. On the U.S. trial, management said enrollment is proceeding at 4 active sites with 7 more being onboarded, but the main internal priority is regulatory approvals in Japan and for Helix, so detailed enrollment updates were limited.
The bull case is that BioCardia appears close to two meaningful regulatory catalysts: CardiAMP submission in Japan and FDA feedback on Helix within weeks. Management also described a potentially large Japan opportunity, ongoing partner interest, and no known safety issues in the Heart Failure II trial, which could support further clinical and commercial progress.
The main risks are regulatory and execution-related. Management said the Japan timeline is fluid, a key risk is if documentation does not meet the required standard and repeat testing is needed, and Helix still depends on FDA accepting the de novo pathway. Financially, cash was only $2.2 million at quarter-end, so the company remains dependent on continued careful burn management and successful regulatory progress.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.3%
- Shares Outstanding
- 15.14M
- Float Shares
- 12.30M
of shares held by institutions
21 13F filers
Buy/sell ratio 7.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cm Management, LLC | 400.00K | ▲ 100.00K |
| Citigroup Inc | 275.03K | ▼ 122.56K |
| Pingora Partners LLC | 159.58K | ▲ 39.20K |
| Vanguard Group Inc | 135.56K | ▲ 39.06K |
| Vanguard Capital Management LLC | 124.59K | 0 |
| Geode Capital Management, LLC | 104.71K | ▲ 38.05K |
| Vanguard Fiduciary Trust Co | 66.27K | 0 |
| Hrt Financial LP | 44.95K | ▲ 44.95K |
| Susquehanna International Group, Llp | 38.81K | ▼ 18 |
| Brown Advisory Inc | 35.54K | 0 |
| Stonex Group Inc. | 33.45K | ▲ 13.43K |
| Citadel Advisors LLC | 22.96K | ▼ 40.43K |
Held by 19 ETFs
Biggest fund positions in BCDA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 16, 26 | Altman Peter | buy | 300 |
| Oct 15, 26 | Altman Peter | buy | 200 |
| Sep 29, 26 | Altman Peter | buy | 1,000 |
| Sep 23, 26 | Altman Peter | buy | 1,900 |
| Sep 3, 26 | Altman Peter | buy | 800 |
| Aug 17, 26 | Altman Peter | buy | 5,400 |
| Aug 13, 26 | Altman Peter | buy | 1,900 |
| Jul 29, 26 | Altman Peter | buy | 5,000 |
| Jul 17, 26 | Altman Peter | buy | 500 |
| Jul 15, 26 | Altman Peter | buy | 1,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BCDA coverage
Recent articles, reports, and earnings notes.
No research on BCDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCDA report →BioCardia (BCDA) Upgraded to Buy: Here's What You Should Know
zacks.com · Nov 17
BioCardia, Inc. (BCDA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
globenewswire.com · Nov 12
BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
globenewswire.com · Nov 9
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
globenewswire.com · Nov 6
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
globenewswire.com · Oct 19
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
globenewswire.com · Oct 7
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
globenewswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.